How A Fully Integrated Transient Antibody Manufacturing Workflow Provided Critical Reagents to the COVID-19 Pandemic Response

Life-saving therapeutic and diagnostic advancements that can mitigate healthcare crises are being discovered at a faster rate than ever before; the biopharmaceutical industry must strive to meet the growing need for speed, quality, and efficiency in high-stakes situations like the COVID-19 pandemic. As researchers seek to rapidly develop potential diagnostics, vaccines, therapies, and cures, they need reliable and efficient partners that will bring their formulations to patients in need.

Traditionally, the transient expression process for rapidly manufacturing a monoclonal antibody (mAb) from initial request through gene synthesis to protein shipment takes anywhere from 7- to 8-weeks, or 50- to 60-days. This is due in large part to managing a demand queue, internal coordination of tasks, and the need to potentially outsource crucial components of the project (i.e., sequencing or plasmid scale-up). However, opting to work with a partner that offers a fully integrated in-house platform can produce significantly higher-speed results without compromising quality or yields. Download the full whitepaper to read a case study that demonstrates how SARS-CoV-2 antibodies were developed and delivered in just 18 days.